AbbVie unveiled a sweeping set of new clinical data at the European Hematology Association (EHA) 2026 Congress, spotlighting advances across its blood cancer portfolio and pipeline in multiple myeloma, lymphoma, leukemia, and related rare hematologic diseases.
The company will present 21 oral and poster presentations spanning investigational and approved therapies, including epcoritamab, venetoclax, etentamig, and pivekimab sunirine-pvzy—underscoring what it calls a continued push to expand treatment options across difficult-to-treat blood cancers.
“The compelling data we are presenting at EHA reflect AbbVie's robust portfolio and pipeline and our ongoing work to advance the treatment and understanding of hematologic cancers,” said Daejin Abidoye, vice president, therapeutic area head, oncology, solid tumor and hematology, AbbVie.
“With this research, we continue our commitment to pioneering innovative solutions that have the potential to elevate standards of care for patients and help address the most pressing challenges in treating blood cancers.”
A major focus of the presentation slate is epcoritamab, a CD3×CD20 bispecific antibody, with multiple late-stage datasets across follicular lymphoma (FL) and large B-cell lymphoma (LBCL).
In the Phase 3 EPCORE FL-1 subgroup analysis, epcoritamab combined with lenalidomide and rituximab (E+R2) showed higher overall response rates than standard R2 therapy across both high- and low-risk patient groups, including older patients and those with poorer prognostic features. The safety profile remained consistent with prior findings, with no new safety signals reported.
In relapsed or refractory LBCL, the EPCORE DLBCL-1 Phase 3 trial showed improved progression-free survival versus investigator’s choice chemotherapy.
However, overall survival did not show a statistically significant improvement. Complete response rates were higher with epcoritamab, and patients also experienced longer duration of response and time to next treatment. Higher rates of severe infections and COVID-19 were noted in the epcoritamab arm.
AbbVie will also highlight multiple datasets on venetoclax, including long-term and real-world evidence across chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
Key findings from GAIA/CLL13 suggest venetoclax-based regimens may deliver sustained benefit across genetically defined subgroups, while the CLL14 study continues to support fixed-duration venetoclax plus obinutuzumab in previously untreated patients with comorbidities.
Real-world REVIVE study data in AML will further explore treatment management practices, including the impact of antimicrobial prophylaxis and supportive care strategies on outcomes with venetoclax-based therapy.
The company will also present early-stage and investigational data across several pipeline assets:
1. Etentamig (ABBV-383) in relapsed/refractory multiple myeloma and light chain amyloidosis, including dose optimization and long-term safety analyses.
2. Pivekimab sunirine-pvzy in blastic plasmacytoid dendritic cell neoplasm (BPDCN), focusing on patients with skin involvement.
Across oral and poster sessions, AbbVie’s presence at EHA 2026 spans combination regimens, comparative effectiveness studies, biomarker analyses, and real-world evidence—reflecting a strategy aimed at both expanding approved indications and advancing earlier-stage innovation.
The data collectively reinforce AbbVie’s positioning in hematologic oncology as it continues to build out a portfolio designed to target multiple disease pathways and treatment settings, from frontline therapy to heavily pretreated patients.
